Recent studies revealed that the genetic ablation of Angptl4 in liver or adipose tissue, as well as targeted pharmacological inhibition of ANGPTL4 in hepatocytes significantly reduced circulating TG and cholesterol levels in mice, protecting them against diet-induced obesity, glucose intolerance, liver steatosis, and atherogenesis [124,132]. The gene discussed is ANGPTL4; the disease is Hepatic steatosis.